[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

Semin Radiat Oncol. 2023 Jul;33(3):287-297. doi: 10.1016/j.semradonc.2023.03.006.

Abstract

PET imaging with 2'-deoxy-2'-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18*
  • Glucose
  • Humans
  • Neoplasms* / diagnostic imaging
  • Neoplasms* / radiotherapy
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals

Substances

  • Fluorodeoxyglucose F18
  • Glucose
  • Radiopharmaceuticals